FR05C0022I1 - - Google Patents

Info

Publication number
FR05C0022I1
FR05C0022I1 FR05C0022C FR05C0022I1 FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed filed Critical
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 true FR05C0022I1 (tr) 2005-06-10
FR05C0022I2 FR05C0022I2 (tr) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (tr) 1995-03-30 2005-05-09

Country Status (36)

Country Link
US (1) US6417191B1 (tr)
EP (1) EP0817637B1 (tr)
JP (1) JP2954357B2 (tr)
KR (1) KR100542536B1 (tr)
CN (1) CN1103593C (tr)
AP (1) AP652A (tr)
AT (1) ATE220551T1 (tr)
AU (1) AU715213B2 (tr)
BR (3) BRPI9607851B8 (tr)
CA (1) CA2216634C (tr)
CZ (1) CZ295940B6 (tr)
DE (3) DE69622386T2 (tr)
DK (1) DK0817637T3 (tr)
EA (1) EA000626B3 (tr)
EE (1) EE04047B1 (tr)
ES (1) ES2179193T3 (tr)
FR (1) FR05C0022I2 (tr)
GE (1) GEP20022647B (tr)
HK (1) HK1009401A1 (tr)
HU (1) HU224010B1 (tr)
IL (1) IL117727A (tr)
LU (1) LU91171I2 (tr)
MX (1) MX9707316A (tr)
MY (1) MY115461A (tr)
NL (1) NL300195I2 (tr)
NO (2) NO313787B1 (tr)
NZ (1) NZ306419A (tr)
OA (1) OA10616A (tr)
PL (1) PL187085B1 (tr)
PT (1) PT817637E (tr)
RO (1) RO117995B1 (tr)
SI (1) SI0817637T1 (tr)
SK (1) SK283825B6 (tr)
TR (1) TR199701074T1 (tr)
UA (1) UA60293C2 (tr)
WO (1) WO1996030025A1 (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709939A (pt) * 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
JP2001525839A (ja) * 1997-05-17 2001-12-11 グラクソ、グループ、リミテッド 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
NZ546873A (en) 2003-10-24 2010-09-30 Immunaid Pty Ltd Method of analysing immune system cycling to monitor and/or treat diseases characterised by the production of regulator T cells
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
CN101674811B (zh) * 2007-02-09 2015-08-19 阿尔法制药有限公司 含有两种或更多种不同物理形态的活性药物成分的剂型
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
JP6749890B2 (ja) 2014-08-12 2020-09-02 モナッシュ ユニバーシティ リンパ指向プロドラッグ
CN118063537A (zh) 2015-09-08 2024-05-24 莫纳什大学 定向淋巴的前药
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CA3077739A1 (en) * 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
KR20220149534A (ko) 2020-02-05 2022-11-08 퓨어테크 엘와이티, 아이엔씨. 신경스테로이드의 지질 전구약물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
BR9709939A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
WO1997049410A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
PL187085B1 (pl) 2004-05-31
CN1185110A (zh) 1998-06-17
US6417191B1 (en) 2002-07-09
DE122005000029I1 (de) 2005-10-06
WO1996030025A1 (en) 1996-10-03
ATE220551T1 (de) 2002-08-15
NO974510D0 (no) 1997-09-29
FR05C0022I2 (tr) 2005-10-21
BRPI9607851B8 (pt) 2019-11-05
CA2216634C (en) 2004-07-20
UA60293C2 (uk) 2003-10-15
CN1103593C (zh) 2003-03-26
NO313787B1 (no) 2002-12-02
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
CZ295940B6 (cs) 2005-12-14
LU91171I2 (fr) 2005-07-04
BR9607851B1 (pt) 2009-01-13
OA10616A (en) 2001-03-15
BRPI9612992B1 (pt) 2020-08-04
EP0817637A1 (en) 1998-01-14
MX9707316A (es) 1997-11-29
IL117727A0 (en) 1996-07-23
EA000626B3 (ru) 2016-04-29
EP0817637B1 (en) 2002-07-17
HK1009401A1 (en) 1999-09-10
KR100542536B1 (ko) 2006-03-23
EA199700203A1 (ru) 1998-02-26
ES2179193T3 (es) 2003-01-16
AP652A (en) 1998-06-19
AP9701089A0 (en) 1997-10-31
SI0817637T1 (en) 2002-10-31
NO2005014I2 (no) 2008-02-11
JPH10511682A (ja) 1998-11-10
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
DE122005000029I2 (de) 2006-04-27
NL300195I1 (nl) 2005-08-01
TR199701074T1 (tr) 1998-02-21
SK129597A3 (en) 1998-07-08
EE04047B1 (et) 2003-06-16
CZ309097A3 (cs) 1998-05-13
HU224010B1 (hu) 2005-04-28
EE9700240A (et) 1998-04-15
SK283825B6 (sk) 2004-02-03
EA000626B1 (ru) 1999-12-29
DE69622386T2 (de) 2003-02-13
GEP20022647B (en) 2002-03-25
NO2005014I1 (no) 2005-06-06
KR19980703420A (ko) 1998-11-05
NO974510L (no) 1997-09-29
JP2954357B2 (ja) 1999-09-27
MY115461A (en) 2003-06-30
AU5497296A (en) 1996-10-16
LU91171I9 (tr) 2018-12-28
CA2216634A1 (en) 1996-10-03
DK0817637T3 (da) 2002-11-11
AU715213B2 (en) 2000-01-20
HUP9801571A3 (en) 2001-04-28
IL117727A (en) 1999-11-30
PL322532A1 (en) 1998-02-02
NL300195I2 (nl) 2005-11-01
BR9607851A (pt) 1998-07-21
RO117995B1 (ro) 2002-12-30

Similar Documents

Publication Publication Date Title
DE69638352D1 (tr)
DE69637714D1 (tr)
FR05C0022I2 (tr)
BR122012014331A2 (tr)
DK143195A (tr)
ECSDI950232S (tr)
IN182969B (tr)
DK0727898T3 (tr)
FR2729785B1 (tr)
ECSDI950229S (tr)
ECSDI950230S (tr)
ECSDI950231S (tr)
ECSDI950223S (tr)
AU1627395A (tr)
DK126096A (tr)
ECSDI950233S (tr)
IN182456B (tr)
IN182291B (tr)
IN185244B (tr)
IN186166B (tr)
CN3037433S (tr)
EP0779578A3 (tr)
CN3037606S (tr)
CN3036648S (tr)
CN3036647S (tr)